Skip to main content
. 2023 Aug 30;17(17):16432–16447. doi: 10.1021/acsnano.2c12857

Figure 6.

Figure 6

Targeted delivery of the Ang/TAT-sgGSS-EVs sensitizes GBM to radiotherapy. (A) Schematic illustration of EVs for in vivo delivery of Cas9 protein and sgRNA for the treatment of brain tumor. (B) Fluorescence images of orthotopic LN229-bearing nude mice following injection of different types of EVs. (C) Luciferase luminescence, sgGSS-cy3, Cas9-GFP and DID-labeled EVs fluorescence from major organs in orthotopic mice model after intravenous injection of different types of EVs. (D) Schematic illustration of the timeline of the LN229 orthotopic tumor model study. (E) Quantified luminescence levels of mice following the indicated treatments. (F) Tumor growth and volume quantification. (G) Survival curves of LN229-bearing mice following the indicated treatments. n = 8 animals per treatment group. (H) Indel frequency of GSS gene in tumor tissues excised from mice on day 28. (I) Sequencing results of GSS gene editing in LN229-bearing mice treated with Ang/TAT-sgGSS-EVs. (J) IHC analysis of GSS and 4-HNE expression in tumor tissues.